Literature DB >> 14507663

Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart.

Peter Dazert1, Konrad Meissner, Silke Vogelgesang, Björn Heydrich, Lothar Eckel, Michael Böhm, Rolf Warzok, Reinhold Kerb, Ulrich Brinkmann, Elke Schaeffeler, Matthias Schwab, Ingolf Cascorbi, Gabriele Jedlitschky, Heyo K Kroemer.   

Abstract

The multidrug resistance protein 5 (MRP5/ABCC5) has been recently identified as cellular export pump for cyclic nucleotides with 3',5'-cyclic GMP (cGMP) as a high-affinity substrate. In view of the important role of cGMP for cardiovascular function, expression of this transport protein in human heart is of relevance. We analyzed the expression and localization of MRP5 in human heart [21 auricular (AS) and 15 left ventricular samples (LV) including 5 samples of dilated and ischemic cardiomyopathy]. Quantitative real-time polymerase chain reaction normalized to beta-actin revealed expression of the MRP5 gene in all samples (LV, 38.5 +/- 12.9; AS, 12.7 +/- 5.6; P < 0.001). An MRP5-specific polyclonal antibody detected a glycoprotein of approximately 190 kd in crude cell membrane fractions from these samples. Immunohistochemistry with the affinity-purified antibody revealed localization of MRP5 in cardiomyocytes as well as in cardiovascular endothelial and smooth muscle cells. Furthermore, we could detect MRP5 and ATP-dependent transport of [(3)H]cGMP in sarcolemma vesicles of human heart. Quantitative analysis of the immunoblots indicated an interindividual variability with a higher expression of MRP5 in the ischemic (104 +/- 38% of recombinant MRP5 standard) compared to normal ventricular samples (53 +/- 36%, P < 0.05). In addition, we screened genomic DNA from our samples for 20 single-nucleotide polymorphisms in the MRP5 gene. These results indicate that MRP5 is localized in cardiac and cardiovascular myocytes as well as endothelial cells with increased expression in ischemic cardiomyopathy. Therefore, MRP5-mediated cellular export may represent a novel, disease-dependent pathway for cGMP removal from cardiac cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507663      PMCID: PMC1868287          DOI: 10.1016/S0002-9440(10)63513-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

Review 1.  Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5.

Authors:  Masashi Adachi; Glen Reid; John D Schuetz
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

2.  Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.

Authors:  Liqi Lai; Theresa M C Tan
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

3.  Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaB-sensitive pathway in alveolar epithelial cells.

Authors:  John J Haddad; Stephen C Land; William O Tarnow-Mordi; Marek Zembala; Danuta Kowalczyk; Ryszard Lauterbach
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

4.  Expression of multidrug resistance protein 4 and 5 in the porcine coronary and pulmonary arteries.

Authors:  Akiko Mitani; Tsutomu Nakahara; Kenji Sakamoto; Kunio Ishii
Journal:  Eur J Pharmacol       Date:  2003-04-11       Impact factor: 4.432

5.  Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.

Authors:  P R Wielinga; G Reid; E E Challa; I van der Heijden; L van Deemter; M de Haas; C Mol; A J Kuil; E Groeneveld; J D Schuetz; C Brouwer; R A De Abreu; J Wijnholds; J H Beijnen; P Borst
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

Review 6.  Role of MRP4 and MRP5 in biology and chemotherapy.

Authors:  J Sampath; M Adachi; S Hatse; L Naesens; J Balzarini; R M Flatley; L H Matherly; J D Schuetz
Journal:  AAPS PharmSci       Date:  2002

7.  Immunolocalization of multidrug resistance protein 5 in the human genitourinary system.

Authors:  Anne T Nies; Herbert Spring; Walter F Thon; Dietrich Keppler; Gabriele Jedlitschky
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

8.  Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR.

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Yukie Miura; Chie Ogawa; Saori Kawauchi; Shoko Higuchi; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

9.  Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy.

Authors:  Konrad Meissner; Bernhard Sperker; Christiane Karsten; Henriette Meyer Zu Schwabedissen; Ute Seeland; Michael Böhm; Sandra Bien; Peter Dazert; Christiane Kunert-Keil; Silke Vogelgesang; Rolf Warzok; Werner Siegmund; Ingolf Cascorbi; Michael Wendt; Heyo K Kroemer
Journal:  J Histochem Cytochem       Date:  2002-10       Impact factor: 2.479

10.  RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation.

Authors:  Vincent Sauzeau; Malvyne Rolli-Derkinderen; Céline Marionneau; Gervaise Loirand; Pierre Pacaud
Journal:  J Biol Chem       Date:  2003-01-09       Impact factor: 5.157

View more
  20 in total

1.  cUMP hydrolysis by PDE3A.

Authors:  Stefan Berrisch; Jessica Ostermeyer; Volkhard Kaever; Solveig Kälble; Denise Hilfiker-Kleiner; Roland Seifert; Erich H Schneider
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-14       Impact factor: 3.000

2.  Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.

Authors:  S Lal; N Sutiman; L L Ooi; Z W Wong; N S Wong; P C S Ang; B Chowbay
Journal:  Pharmacogenomics J       Date:  2016-03-15       Impact factor: 3.550

3.  Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.

Authors:  Markus Grube; Sabine Ameling; Michel Noutsias; Kathleen Köck; Ivonne Triebel; Karina Bonitz; Konrad Meissner; Gabriele Jedlitschky; Lars R Herda; Markus Reinthaler; Maria Rohde; Wolfgang Hoffmann; Uwe Kühl; Heinz-Peter Schultheiss; Uwe Völker; Stephan B Felix; Karin Klingel; Reinhard Kandolf; Heyo K Kroemer
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 4.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

5.  Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation.

Authors:  Henriette E U Meyer Zu Schwabedissen; Markus Grube; Björn Heydrich; Knud Linnemann; Christoph Fusch; Heyo K Kroemer; Gabriele Jedlitschky
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 6.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

7.  Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Alexander Staudt; Christiane Trimpert; Michel Noutsias; Uwe Kühl; Matthias Pauschinger; Heinz-Peter Schultheiss; Markus Grube; Michael Böhm; Gert Baumann; Uwe Völker; Heyo K Kroemer; Stephan B Felix
Journal:  J Mol Med (Berl)       Date:  2007-10-09       Impact factor: 4.599

8.  Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux.

Authors:  Pradeep K Karla; Tim L Quinn; Betty L Herndon; Priscilla Thomas; Dhananjay Pal; Ashim Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2009-04       Impact factor: 2.671

9.  Differential expression of multidrug resistance protein 5 and phosphodiesterase 5 and regulation of cGMP levels in phasic and tonic smooth muscle.

Authors:  Othman Al-Shboul; Sunila Mahavadi; Wimolpak Sriwai; John R Grider; Karnam S Murthy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-13       Impact factor: 4.052

10.  Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation.

Authors:  Yassine Sassi; Larissa Lipskaia; Grégoire Vandecasteele; Viacheslav O Nikolaev; Stéphane N Hatem; Fleur Cohen Aubart; Frans G Russel; Nathalie Mougenot; Cédric Vrignaud; Philippe Lechat; Anne-Marie Lompré; Jean-Sébastien Hulot
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.